Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.
Back to All News
All Market News
Other Market News
Alliance Witan – Final Results
Hargreaves Services Announce 2nd Tranche of Renewable Energy Land Assets Sold
Aviva 2025 Results Announcement
Reckitt Benckiser – Results for the Year Ended 31 December 2025
Hargreaves Services – Positive Contract Awards in Service
FW Thorpe – Interim Results
Sign up for our Stock News Highlights
Delivered to your inbox every Friday